Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
3D Medicines (1244 HK)
Watchlist
25
Analysis
Health Care
•
China
3D Medicines Inc. operates as a commercial-stage biopharmaceutical company. The Company focuses on the development of differentiated immuno-oncology drugs. 3D Medicines conducts businesses in China.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
CPMC
•
18 Aug 2024 10:00
HSCI Index Rebalance: 38 Adds, 29 Deletes & Changes to Southbound Stock Connect
There are 38 adds and 29 deletes for the HSCI at the September rebalance to take the number of index constituents up to 518. There will be a lot of...
Brian Freitas
Follow
861 Views
Share
bullish
•
Stella International
•
03 Jul 2024 06:30
HSCI Index Rebalance Preview and Stock Connect: Potential Changes in September
There could be nearly 80 adds/deletes for the HSCI in September. That will trigger changes to the Southbound Stock Connect list and increase flows...
Brian Freitas
Follow
856 Views
Share
bearish
•
Quantitative Analysis
•
10 Dec 2023 10:10
Hong Kong Connect Flows (Dec 8th): Meituan, CNOOC, Tencent, Wuxi Biologics, HKEx, Xiaomi
We analyzed southbound Hong Kong connect flows in the past week and highlight flows for Meituan, CNOOC, Tencent, Wuxi Biologics, HKEx, Xiaomi.
Ke Yan, CFA, FRM
Follow
569 Views
Share
bearish
•
Quantitative Analysis
•
04 Dec 2023 10:00
Hong Kong Connect Flows (November): Five Months of Inflows Despite New Low
We analyzed the Hong Kong Connect Scheme for November and highlight flows for TraHK, Xpeng, SMIC, CSOP Hang Seng ETF, Ping An Insurance.
Ke Yan, CFA, FRM
Follow
688 Views
Share
bearish
•
Quantitative Analysis
•
05 Nov 2023 10:10
Hong Kong Connect Flows (Nov 3rd): Li Ning, SMIC, Xiaomi
We analyzed southbound Hong Kong connect flows in the past week and highlight flows for Li Ning, Semiconductor Manufacturing International, Xiaomi,...
Ke Yan, CFA, FRM
Follow
841 Views
Share
First
Previous
1
2
3
4
5
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x